CERENOME, INC. (CNSY): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-13 16:51 ET
- Event date
- 2026-11-13
- Accession no.
- 0001193125-26-460887
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
Cerenome reports third quarter 2026 results and CNSide and REYOBIQ updates
Cerenome reported third quarter revenue of $0.7 million and a net loss of $8.7 million, compared with $4.4 million a year earlier. It also disclosed expanded CNSide payer coverage, completion of Phase 2 ReSPECT-GBM enrollment and interim ReSPECT-LM findings with no dose-limiting toxicities reported in the first 10 patients.
- Total revenue was $0.7 million, consisting entirely of net diagnostic revenue.
- Net loss was $8.7 million, or $1.14 per share, compared with $4.4 million, or $1.03 per share, a year earlier.
- Cash, cash equivalents and investments totaled $4.9 million as of September 30, 2026.
- Enrollment in the Phase 2 ReSPECT-GBM study was completed in October; topline data are expected in mid-2027.
earningsproduct
Items reported
- Item 2.02: Results of Operations and Financial Condition
The company publicly announced results of operations or financial condition for a completed period, most often a quarterly earnings release. The release itself is usually attached as Exhibit 99.1. Information under Item 2.02 is generally "furnished" rather than "filed". - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | 8-K | cnsy-20261113.htm |
| EX-99.1 | EX-99.1 | cnsy-ex99_1.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.